Kura Oncology’s (KURA) Market Outperform Rating Reiterated at JMP Securities

Kura Oncology (NASDAQ:KURA)‘s stock had its “market outperform” rating reissued by equities researchers at JMP Securities in a report issued on Thursday,Benzinga reports. They currently have a $28.00 price target on the stock. JMP Securities’ price target indicates a potential upside of 244.15% from the stock’s current price.

KURA has been the subject of a number of other research reports. UBS Group initiated coverage on Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. Scotiabank cut their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. Jefferies Financial Group cut their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.13.

Kura Oncology Stock Performance

NASDAQ KURA traded down $0.91 during trading hours on Thursday, reaching $8.14. The stock had a trading volume of 2,460,447 shares, compared to its average volume of 1,770,848. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a market cap of $632.66 million, a P/E ratio of -3.45 and a beta of 0.78. The stock has a fifty day moving average of $8.83 and a 200 day moving average of $15.16.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter in the previous year, the firm posted ($0.50) EPS. Sell-side analysts predict that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Transactions at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,255 shares of company stock valued at $100,739. 5.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new position in shares of Kura Oncology in the 2nd quarter valued at $541,000. AQR Capital Management LLC boosted its stake in Kura Oncology by 251.5% in the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after acquiring an additional 58,422 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after purchasing an additional 1,976 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Kura Oncology during the third quarter worth about $25,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kura Oncology by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock valued at $288,000 after purchasing an additional 5,788 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.